Compare Jones Lang LaSalle Inc (JLL) vs Zoetis Inc (ZTS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Jones Lang LaSalle Inc vs Zoetis Inc — how do they compare? Jones Lang LaSalle Inc trades at $326.44 (market cap $15.12B), while Zoetis Inc trades at $75.19 (market cap $31.95B). The key difference: Zoetis Inc is far larger — about 2.1× Jones Lang LaSalle Inc's market cap, and Zoetis Inc pays a 2.78% dividend while Jones Lang LaSalle Inc pays none. Which is the better fit depends on your goals.
| JLL | ZTS | |
|---|---|---|
Market Cap | $15.12B | $31.95B |
Sector | Real Estate | Health |
52-Week High | $358.66 | $156.76 |
52-Week Low | $253.48 | $71.91 |
Enterprise Value | $18.66B | $39.24B |
Dividend Yield | — | 2.78% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
JLL trades at $325.94, down 1.43% today, but maintains a bullish technical outlook with strong moving average signals. The company shows solid fundamental improvement with revenue growing from $20.9B in 2022 to $26.1B in 2025, while net income margin expanded to 3.35%. Recent earnings beats and positive analyst coverage (54.55% buy rating) support the stock's upward trajectory, with a consensus price target of $405.50 representing 24.4% upside potential.
JLL presents a compelling investment case with improving profitability, strong cash flow generation ($1.19B operating cash flow in 2025), and positive business momentum in commercial real estate services. Key risks include exposure to commercial real estate cycles and potential economic slowdowns, but the company's debt-to-asset ratio improvement to 9.32% and consistent earnings beats provide fundamental support for continued growth.
Zoetis (ZTS) trades at $76.05, down 0.67% on the day, with a neutral technical signal and bearish moving averages. The company maintains strong fundamentals with a 28.03% net income margin and 67.75% ROE, though Q1 2026 earnings missed expectations. Recent news highlights multiple securities class action lawsuits filed against the company, creating near-term uncertainty despite the launch of new product Lenivia in Canada and EU markets.
The stock presents a mixed outlook with attractive valuation metrics (P/E 12.55) and analyst consensus price target of $101.43 suggesting 33% upside potential. However, legal challenges and the recent earnings miss pose significant near-term risks. Institutional sentiment remains divided with 47% buy ratings versus 53% hold ratings, indicating cautious optimism amid legal headwinds.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Jones Lang LaSalle Inc
Jones Lang LaSalle provides a wide range of real estate-related services to owners, occupiers, and investors worldwide, including leasing, property and project management, and capital markets advisory. JLL's investment management arm, LaSalle Investment Management, manages over $70 billion for clients across diverse public and private real estate strategies.
Read more on JLL →About Zoetis Inc
Zoetis sells anti-infectives, vaccines, parasiticides, diagnostics, and other health products for animals. The firm earns slightly less than half of total revenue from production animals (cattle, pigs, poultry, and so on), and more than half from companion animal (dogs, horses, cats) products make up the other half. Its U.S. business is heavily skewed toward companion animals, while its international business is slightly skewed toward production animals. The firm has the largest market share in the industry and was previously Pfizer's animal health unit.
Read more on ZTS →
